Back CoVLP Arabic Vakcína Medicago-GlaxoSmithKline proti covidu-19 Czech CoVLP German CoVLP Spanish CoVLP ID CoVLP Japanese Medicago (bakuna ng COVID-19) Tagalog CoVLP Ukrainian
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Trade names | Covifenz |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
CoVLP (brand name Covifenz) was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.[6]
It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.[7][8][9][10]
The Medicago method to manufacture CoVLP was a "molecular farming" technology regarded as rapid, low-cost, and safe.[8][11] It was proposed specifically for production of COVID-19 vaccines.[12][13]
In February 2022, Health Canada authorized use of CoVLP for preventing COVID-19 infection in adults 18 to 64 years old.[3] The authorization stated there was an efficacy rate of 71% after two vaccinations against symptoms of COVID-19 disease and 100% efficacy against severe COVID-19 infections.[3]
- ^ "Product monograph for Covifenz" (PDF). Medicago, Inc. 24 February 2022.
- ^ "Medicago Covifenz COVID-19 vaccine". Health Canada. 24 February 2022. Retrieved 29 May 2022.
- ^ a b c "Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age" (Press release). Health Canada. 24 February 2022. Retrieved 24 February 2022.
- ^ "Summary Basis of Decision (SBD) for Covifenz". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ "Covifenz (virus-like particles (VLP) of SARS-CoV-2 spike protein)". Health Canada. 24 February 2022. Retrieved 31 May 2022.
- ^ Cite error: The named reference
laverywas invoked but never defined (see the help page). - ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
- ^ a b LeBlanc Z, Waterhouse P, Bally J (December 2020). "Plant-Based Vaccines: The Way Ahead?". Viruses. 13 (1): 5. doi:10.3390/v13010005. PMC 7822169. PMID 33375155.
- ^ St Philip E, Favaro A, MacLeod M (14 July 2020). "The hunt for a vaccine: Canadian company begins human testing of COVID-19 candidate". CTV News. Retrieved 14 July 2020.
- ^ Chander V (14 July 2020). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. Retrieved 14 July 2020.
- ^ Fischer R, Buyel JF (2020). "Molecular farming - The slope of enlightenment". Biotechnology Advances. 40: 107519. doi:10.1016/j.biotechadv.2020.107519. PMID 31954848. S2CID 210830170.
- ^ Dhama K, Natesan S, Iqbal Yatoo M, Patel SK, Tiwari R, Saxena SK, Harapan H (December 2020). "Plant-based vaccines and antibodies to combat COVID-19: current status and prospects". Human Vaccines & Immunotherapeutics. 16 (12): 2913–2920. doi:10.1080/21645515.2020.1842034. PMC 7754927. PMID 33270484.
- ^ Balfour H (15 April 2020). "Plant bio-factories contributing to the COVID-19 fight". Drug Target Review. Retrieved 30 January 2021.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search